PEP-PT141-OXY • RESEARCH USE ONLY

PT-141 / Oxytocin

A synergistic nasal peptide blend combining PT-141, a centrally acting libido and arousal peptide, with Oxytocin, the hormone of connection and bonding. Together, they enhance sexual desire, arousal, emotional intimacy, and interpersonal connection, making this formulation ideal for on-demand intimacy and relational support.

5 mg / 10 mg

Per Bottle

— 31 mcg / 62 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Use it as needed, typically 30–60 minutes before the desired effect. Do NOT use daily. Most users take it 2–3 times per week, leaving 24–48 hours between doses.

Starting

62 mg / 125 mcg (2 sprays)

Medium

125 mg / 250 mcg (4 sprays)

Higher

186 mg / 375 mcg (6 sprays)

Key Benefits

Provides synergistic support for sexual desire and arousal, enhances emotional bonding and intimacy, elevates mood, reduces anxiety, and supports confidence and connection during intimate or social experiences.

Guidance

Start with 2 sprays and assess response
Increase gradually only if needed
Avoid repeated daily use
Do not exceed 6 sprays per use unless directed
Ideal for intimacy, emotional connection, and libido support
Effects are centrally mediated (not vascular) and may last several hours
Can be stacked cautiously with Kisspeptin for enhanced libido and bonding (use lower doses when stacking)

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA